Maxim Group analyst Jason McCarthy reiterated a Buy rating on Femasys (FEMY – Research Report) yesterday and set a price target of $5.00. The company’s shares opened today at $1.13.
According to TipRanks, McCarthy is an analyst with an average return of -38.0% and a 15.11% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Daré Bioscience, and Lineage Cell Therapeutics.
Currently, the analyst consensus on Femasys is a Strong Buy with an average price target of $7.33.
See Insiders’ Hot Stocks on TipRanks >>
FEMY market cap is currently $12.76M and has a P/E ratio of -1.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Femasys Inc is a biomedical company focused on transforming women’s healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Read More on FEMY:
- Femasys holds promotional launch of FemCerv
- Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
- Femasys announces enrollment over 25% complete for FemaSeed de novo trial
- Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
- Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
